Safety and Efficacy of RSV Vaccines in Older Adults

Key Takeaways

• ConquerRSV, AReSVi-006, and RENOIR trials show significant efficacy in preventing RSV-related illness in older adults.
• The vaccines have demonstrated generally well-tolerated safety profiles with manageable side effects.
• Immunogenicity and protective benefits data support the potential role of these vaccines in reducing RSV burden.
• Ongoing monitoring and research are crucial for optimizing vaccine strategies and ensuring long-term safety.